欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > CellCycle/Checkpoint > Trilaciclib

浏览历史

T27103

Trilaciclib

源叶(MedMol) 98%
  • 英文名:
  • Trilaciclib
  • 别名:
  • G1T28
  • CAS号:
  • 1374743-00-6
  • 分子式:
  • C24H30N8O
  • 分子量:
  • 446.548
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) T27103-5mg 98% ¥620.00元 6 - - - EA 加入购物车
源叶(MedMol) T27103-10mg 98% ¥930.00元 5 - - - EA 加入购物车
源叶(MedMol) T27103-25mg 98% ¥1860.00元 4 - - - EA 加入购物车
源叶(MedMol) T27103-100mg 98% ¥5380.00元 预计交期:2-3天 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 产品描述:

    Trilaciclib 是 CDK4/6 的抑制剂,对于 CDK4 和 CDK6 的 IC50 值分别为 1 nM 和 4 nM。

  • 靶点: IC50: 1 nM (CDK4), 4 nM (CDK6);CDK
  • 体外研究:
    Incubation with Trilaciclib (G1T28) for 24 hours induces a robust G1 cell-cycle arrest (time=0). By 16 hours after Trilaciclib hydrochloride washout, cells have reentered the cell cycle and demonstrate cell-cycle kinetics similar to untreated control cells. These results demonstrate that Trilaciclib causes a transient, and reversible G1 arrest. A transient Trilaciclib-mediated G1 cell-cycle arrest in CDK4/6-sensitive cells decreases the in vitro toxicity of a variety of commonly used cytotoxic chemotherapy agents associated with myelosuppression.
  • 体内研究:
    Trilaciclib (G1T28) treatment results in a robust and dose-dependent suppression of proliferation in HSPCs at 12 hours, with EdU incorporation returning near baseline levels in a dose-dependent manner by 24 hours after administration. These data demonstrate that a single oral dose of Trilaciclib can produce reversible cell-cycle arrest in HSPCs in a dose-dependent manner in vivo. Mice given 100 mg/kg Trilaciclib 30 minutes prior to etoposide treatment, exhibits only background levels of caspase-3/7 activity. These data demonstrate that Trilaciclib can protect the bone marrow from chemotherapy-induced apoptosis in vivo. The data demonstrate that treatment with Trilaciclib prior to 5-FU likely decreases 5-FU-induced damage by chemotherapy in HSPCs, thus accelerating blood count recovery after chemotherapy.
  • 参考文献:
    1.Bisi JE, et al. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15(5):783-93.
  • 溶解性: soluble  in  DMSO
  • 保存条件: -20°C
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 2.239 ml 11.197 ml 22.394 ml
    5 mM 0.448 ml 2.239 ml 4.479 ml
    10 mM 0.224 ml 1.12 ml 2.239 ml
    50 mM 0.045 ml 0.224 ml 0.448 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。